Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Operating Leases: 2019-2024

Historic Operating Leases for ImmunityBio (IBRX) over the last 6 years, with Dec 2024 value amounting to $34.8 million.

  • ImmunityBio's Operating Leases fell 5.36% to $41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.4 million, marking a year-over-year decrease of 5.36%. This contributed to the annual value of $34.8 million for FY2024, which is 23.04% down from last year.
  • According to the latest figures from FY2024, ImmunityBio's Operating Leases is $34.8 million, which was down 23.04% from $45.2 million recorded in FY2023.
  • ImmunityBio's Operating Leases' 5-year high stood at $50.7 million during FY2022, with a 5-year trough of $16.2 million in FY2020.
  • Its 3-year average for Operating Leases is $43.6 million, with a median of $45.2 million in 2023.
  • Its Operating Leases has fluctuated over the past 5 years, first spiked by 147.72% in 2021, then fell by 23.04% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Operating Leases stood at $16.2 million in 2020, then soared by 147.72% to $40.1 million in 2021, then grew by 26.60% to $50.7 million in 2022, then fell by 10.82% to $45.2 million in 2023, then fell by 23.04% to $34.8 million in 2024.